Dr. David Burrow serves as the Director of the Office of Scientific Investigations (OSI), within the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Compliance (OC). In this role, Dr. Burrow leads efforts to shield the American public from unsafe and ineffective drug products. His leadership in the Agency’s Bioresearch Monitoring (BIMO) program includes the development and implementation of policies, surveillance activities, and compliance strategies for CDER-regulated products. Additionally, he oversees the enforcement of clinical and non-clinical drug product studies, bioequivalence studies, human subject protections, post-market adverse drug experience reporting requirements, risk evaluation and mitigation strategies, and post marketing requirements. Dr. Burrow holds a Doctor of Pharmacy from Duquesne University, and a Juris Doctorate from Widener University School of Law. He is licensed to practice law in the State of Maryland.